ARTICLE | Company News
Elan and Biogen to develop Antegren
August 17, 2000 7:00 AM UTC
ELN and BGEN signed a global, exclusive deal to develop, manufacture and commercialize ELN's Antegren natalizumab, a humanized monoclonal antibody in Phase II testing to treat multiple sclerosis and C...